SecBot SecBot
8-K ·Filed Nov 6, 2026

ACRV

Acrivon Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed10d 17h ago SEC0001193125-26-450779
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Watch for the November 10 KOL webcast for further detail on the ACR-525 development plan and EoE clinical strategy. The lack of milestone/royalty obligations removes future cash overhang but the undisclosed upfront cost and the company's $75M market cap raise questions about cash runway for both the new I&I programs and existing oncology pipeline.

DirectionNeutral
Confidencemedium
Horizonweeks

ACR-525

● Neutral Named in this 8-K
Impact
Phase
Phase 2-ready (Phase 1 completed)
Time to market
ACR-525 is Phase 2-ready but has not yet initiated a Phase 2 trial. Assuming successful development, an approval in EoE would likely be several years away (3-5+ years minimum).
Next catalyst
None dated

What to watchWatch the November 10 KOL webcast for clinical development strategy and the November 12 Q3 earnings call for cash position updates. The undisclosed acquisition cost makes it hard to assess the financial impact on Acrivon's ~$75M market cap company. Any subsequent financing or partnership announcement would be a key signal.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.61
T+0 close · Nov 6, 2026 · via day close
Latest settled
−9.94%
T+5 · $1.45
Vs SPY
−12.53%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $1.61entry
  2. T+1 · 8d ago −1.86%α −4.23% · $1.58
  3. T+5 · 4d ago −9.94%α −12.53% · $1.45
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Acrivon Therapeutics acquired Aqilion AB's Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program for an undisclosed cash sum with no future milestone or royalty obligations. The acquisition establishes immunology and inflammation as a new strategic pillar alongside oncology, with eosinophilic esophagitis targeted as the first potential indication.

Key Facts

  • Acquired ACR-525 (formerly AQ280), a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ inhibitor program from Aqilion AB
  • Consideration was an undisclosed cash payment with no future milestone or royalty obligations
  • Concurrently terminated all future royalty and milestone obligations on ACR-525 previously agreed between Aqilion and LEO Pharma
  • Eosinophilic esophagitis (EoE) targeted as first potential indication using a formulation designed for difficulty swallowing
  • Acrivon's AP3 platform profiling characterized ACR-525 as a highly selective JAK1 inhibitor with minimal off-target effects
  • Company to host a webcast with key opinion leaders on November 10, 2026

Financial Impact

Undisclosed cash consideration; no future milestone or royalty payments

cash

Risk Factors

  • Undisclosed acquisition cost could be material relative to $75M market cap
  • ACR-525 has not yet been tested in EoE patients; Phase 1 data were in healthy volunteers or other indications
  • Integration of I&I programs may require additional expertise and resource allocation away from oncology pipeline
  • No revenue from acquired assets; all programs are preclinical or Phase 2-ready with no approved products

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-450779
Document: acrv-ex99_1.htm0001193125-26-450779
Document: 0001193125-26-450779-index-headers.html0001193125-26-450779
Document: 0001193125-26-450779-index.html0001193125-26-450779
Document: 0001193125-26-450779.txt0001193125-26-450779

Track record

8 reports on ACRV

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry $1.45 Now $1.46 +0.69% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.57 Now $1.46 −7.01% settles Feb 9
  3. Nov 6, 202610d ago 8-K Neutral 5/10 Viewing Entry $1.61 Now $1.46 −9.32% settles Feb 4
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $1.61 Now $1.46 −9.32% settles Feb 4
  5. Jul 21, 202616w ago Press Release Neutral 3/10 Entry $1.68 to $1.76 Now $1.46 −13.10% ▲ +4.76% +1.50% vs SPY
  6. May 22, 202625w ago DEFA14A Neutral 3/10 Entry $1.67 to $2.39 Now $1.46 −12.57% ▲ +43.11% +40.39% vs SPY
  7. Apr 30, 202628w ago DEFA14A Neutral 2/10 Entry $1.85 to $1.56 Now $1.46 −21.08% ▼ −15.68% −18.78% vs SPY
  8. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $1.70 to $1.52 Now $1.46 −14.12% ▼ −10.59% −24.93% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 7h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026